Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More
Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More
BIOCON LTD | ALEMBIC LTD | BIOCON LTD/ ALEMBIC LTD |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 41.4 | 51.7 | 80.1% | View Chart |
P/BV | x | 7.2 | 2.1 | 342.1% | View Chart |
Dividend Yield | % | 0.2 | 0.5 | 33.2% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BIOCON LTD Mar-18 |
ALEMBIC LTD Mar-18 |
BIOCON LTD/ ALEMBIC LTD |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,188 | 72 | 1,650.0% | |
Low | Rs | 305 | 34 | 899.7% | |
Sales per share (Unadj.) | Rs | 68.7 | 4.7 | 1,462.0% | |
Earnings per share (Unadj.) | Rs | 7.6 | 6.1 | 123.7% | |
Cash flow per share (Unadj.) | Rs | 14.0 | 6.2 | 223.7% | |
Dividends per share (Unadj.) | Rs | 1.00 | 0.20 | 500.0% | |
Dividend yield (eoy) | % | 0.1 | 0.4 | 35.5% | |
Book value per share (Unadj.) | Rs | 86.3 | 40.7 | 212.4% | |
Shares outstanding (eoy) | m | 600.00 | 267.03 | 224.7% | |
Bonus/Rights/Conversions | IS | - | - | ||
Price / Sales ratio | x | 10.9 | 11.3 | 96.4% | |
Avg P/E ratio | x | 98.9 | 8.7 | 1,139.5% | |
P/CF ratio (eoy) | x | 53.4 | 8.5 | 630.2% | |
Price / Book Value ratio | x | 8.6 | 1.3 | 663.9% | |
Dividend payout | % | 13.2 | 3.3 | 404.1% | |
Avg Mkt Cap | Rs m | 447,900 | 14,139 | 3,167.8% | |
No. of employees | `000 | 6.1 | NA | - | |
Total wages/salary | Rs m | 9,311 | 207 | 4,489.4% | |
Avg. sales/employee | Rs Th | 6,705.8 | NM | - | |
Avg. wages/employee | Rs Th | 1,514.2 | NM | - | |
Avg. net profit/employee | Rs Th | 736.9 | NM | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 41,234 | 1,255 | 3,285.1% | |
Other income | Rs m | 2,062 | 370 | 557.0% | |
Total revenues | Rs m | 43,296 | 1,625 | 2,663.7% | |
Gross profit | Rs m | 8,291 | 111 | 7,462.6% | |
Depreciation | Rs m | 3,851 | 38 | 10,187.8% | |
Interest | Rs m | 615 | 2 | 36,176.5% | |
Profit before tax | Rs m | 5,887 | 442 | 1,332.5% | |
Minority Interest | Rs m | 213 | 0 | - | |
Prior Period Items | Rs m | 0 | 1,212 | 0.0% | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1,569 | 24 | 6,551.1% | |
Profit after tax | Rs m | 4,531 | 1,630 | 278.0% | |
Gross profit margin | % | 20.1 | 8.9 | 227.2% | |
Effective tax rate | % | 26.7 | 5.4 | 491.6% | |
Net profit margin | % | 11.0 | 129.8 | 8.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 41,486 | 1,867 | 2,221.9% | |
Current liabilities | Rs m | 21,413 | 591 | 3,622.0% | |
Net working cap to sales | % | 48.7 | 101.6 | 47.9% | |
Current ratio | x | 1.9 | 3.2 | 61.3% | |
Inventory Days | Days | 64 | 94 | 67.9% | |
Debtors Days | Days | 94 | 74 | 128.1% | |
Net fixed assets | Rs m | 50,661 | 1,791 | 2,828.8% | |
Share capital | Rs m | 3,000 | 534 | 561.7% | |
"Free" reserves | Rs m | 48,808 | 10,324 | 472.8% | |
Net worth | Rs m | 51,808 | 10,858 | 477.2% | |
Long term debt | Rs m | 17,898 | 41 | 43,441.7% | |
Total assets | Rs m | 99,897 | 11,591 | 861.9% | |
Interest coverage | x | 10.6 | 260.9 | 4.1% | |
Debt to equity ratio | x | 0.3 | 0 | 9,104.3% | |
Sales to assets ratio | x | 0.4 | 0.1 | 381.1% | |
Return on assets | % | 5.2 | 14.1 | 36.6% | |
Return on equity | % | 8.7 | 15.0 | 58.3% | |
Return on capital | % | 9.6 | 15.2 | 63.4% | |
Exports to sales | % | 0 | 1.5 | 0.0% | |
Imports to sales | % | 0 | 21.0 | 0.0% | |
Exports (fob) | Rs m | NA | 19 | 0.0% | |
Imports (cif) | Rs m | NA | 263 | 0.0% | |
Fx inflow | Rs m | 12,058 | 19 | 62,154.6% | |
Fx outflow | Rs m | 7,348 | 264 | 2,785.2% | |
Net fx | Rs m | 4,710 | -244 | -1,927.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 6,621 | 236 | 2,807.9% | |
From Investments | Rs m | -6,840 | -224 | 3,053.6% | |
From Financial Activity | Rs m | -2,397 | -27 | 9,011.3% | |
Net Cashflow | Rs m | -2,612 | -15 | 17,648.6% |
Indian Promoters | % | 40.4 | 64.0 | 63.1% | |
Foreign collaborators | % | 20.6 | 0.0 | - | |
Indian inst/Mut Fund | % | 8.4 | 0.2 | 4,200.0% | |
FIIs | % | 10.7 | 9.7 | 110.3% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 19.9 | 26.1 | 76.2% | |
Shareholders | 109,995 | 54,701 | 201.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BIOCON LTD With: VENUS REMEDIES ORCHID PHARMA LTD SANOFI INDIA TTK HEALTHCARE SHASUN PHARMA
Compare BIOCON LTD With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
| |
Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.
For the quarter ended December 2018, ALEMBIC LTD has posted a net profit of Rs 32 m (down 41.9% YoY). Sales on the other hand came in at Rs 243 m (down 18.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.
For the quarter ended September 2018, ALEMBIC LTD has posted a net profit of Rs 294 m (up 4.0% YoY). Sales on the other hand came in at Rs 336 m (up 3.1% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.
For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
More Views on NewsThe real estate sector is ready to make a comeback. This is the stock to consider buying.
During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.
Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.
Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.
Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.
More
| |